approxim
one
third
patient
advanc
human
epiderm
growth
factor
receptor
neuposit
breast
cancer
respond
trastuzumab
monotherapi
human
antibodi
howev
de
novo
acquir
antibodi
resist
one
major
limit
trastuzumab
therapi
warrant
search
therapeut
strategi
one
remark
featur
adenoviru
adv
base
vaccin
abil
induc
except
high
sustain
frequenc
transgen
productspecif
tcell
respons
studi
construct
two
recombin
adv
adv
ova
adv
express
ovalbumin
ova
assess
advinduc
antigenspecif
cellular
immun
respons
preventivetherapeut
antitumor
immun
demonstr
adv
ova
stimul
effici
ovaspecif
cytotox
lymphocyt
ctl
natur
killer
respons
lead
prevent
longterm
immun
ovaexpress
melanoma
wildtyp
mice
demonstr
adv
stimul
ctl
respons
lead
signific
reduct
breast
carcinogenesi
transgen
fvbneun
mice
littl
therapeut
effect
preexist
tumor
even
earli
stage
mm
contrast
antibodi
therapi
capabl
complet
inhibit
tumor
growth
earli
stage
fail
erad
wellestablish
breast
tumor
mm
interestingli
combinatori
immunotherapi
antibodi
adv
vaccin
capabl
cure
studi
mice
bear
wellestablish
breast
tumor
significantli
delay
death
remain
six
tumorbear
mice
taken
togeth
result
suggest
adjuv
effect
adv
antibodi
therapi
wellestablish
breast
tumor
transgen
fvbneun
mice
combinatori
immunotherapi
trastuzumab
adv
vaccin
may
use
new
therapeut
strategi
treatment
advanc
breast
cancer
protooncogen
human
epiderm
growth
factor
receptor
sequenc
homolog
rat
neu
genecod
protein
neu
origin
detect
rat
neuroblastoma
cell
tyrosin
kinas
receptor
belong
epiderm
growth
factor
receptor
famili
compos
extracellular
transmembran
intracellular
domain
breast
cancer
common
cancer
among
women
western
world
protein
overexpress
case
breast
cancer
becom
attract
target
antigen
ag
select
overexpress
malign
cell
ii
immun
respons
frequent
found
patient
breast
cancer
indic
selftoler
broken
human
although
overexpress
often
associ
poor
prognosi
permit
novel
therapi
direct
human
monoclon
antibodi
ab
trastuzumab
possibl
best
known
howev
women
sooner
later
develop
resist
trastuzumab
warrant
search
therapeut
strategi
cytotox
lymphocyt
ctl
import
role
host
defens
virus
intracellular
bacteria
tumor
reason
vaccin
capabl
induc
strong
ctl
respons
becom
major
goal
field
tumor
immun
replicationdefici
adenovirus
adv
found
effect
vaccin
vector
mimic
natur
infect
stimul
innat
immun
respons
lead
develop
effect
tcell
respons
vaccineencod
ag
therefor
genet
vaccin
base
upon
recombin
adv
use
immun
infecti
diseas
ebola
sar
human
immunodefici
viru
vaccin
ovalbumin
ova
express
recombin
adv
stimul
effici
ovaspecif
ctl
respons
lead
protect
viru
challeng
addit
recombin
adv
also
appli
induct
antitumor
immun
studi
recombin
adv
vaccin
shown
induc
effici
prophylact
antitumor
immun
exampl
vaccin
tyrosinaserel
proteinexpress
adv
induc
tyrosinaserel
proteinspecif
tcell
respons
lead
prevent
immun
tyrosinaserel
proteinexpress
melanoma
reduct
melanoma
relaps
surgeri
adv
adv
vaccin
stimul
ab
ctl
respons
lead
prevent
antitumor
immun
wildtyp
mice
howev
therapeut
efficaci
remain
controversi
exampl
ineffect
adv
vaccin
demonstr
even
administ
earli
one
two
day
tumor
cell
seed
wildtyp
mice
convers
investig
shown
recombin
adv
vaccin
effici
erad
advanc
establish
murin
breast
cancer
wildtyp
mice
studi
assess
tcell
respons
antitumor
immun
deriv
vaccin
two
recombin
adv
adv
ova
adv
express
ova
ovaexpress
melanoma
breast
cancer
respect
addit
compar
therapeut
effici
ab
therapi
adv
vaccin
combin
two
wellestablish
breast
cancer
transgen
tg
mice
reagent
cell
line
anim
monoclon
ab
mous
ab
reactiv
rat
oncogenencod
molecul
obtain
american
tissu
type
collect
rockvil
md
biotinlabel
ab
obtain
pharmingen
canada
mississauga
ontario
canada
fluorescein
isothiocyan
fitc
conjug
ab
specif
phycoerythrin
pe
label
b
ova
tetram
pelabel
q
peptid
pdslrdlsvf
tetram
obtain
beckman
coulter
san
diego
ca
nih
tetram
facil
bethesda
md
respect
major
histocompat
complex
class
b
restrict
ovai
siinfekl
peptid
irrelev
peptid
feqntaqp
synthes
multipl
peptid
system
san
diego
ca
highli
lung
metastat
ovatransfect
melanoma
cell
line
gener
laboratori
mous
breast
cancer
cell
line
q
deriv
spontan
breast
cancer
tumor
obtain
dr
kipp
univers
california
san
diego
ca
natur
killer
nk
sensit
tumor
cell
line
obtain
american
tissu
cell
collect
rockvil
md
femal
wildtyp
b
mice
fvb
njtgn
mmtvneu
fvbneun
q
tg
mice
express
rat
neu
control
mous
mammari
tumor
viru
promot
obtain
jackson
laboratori
bar
harbor
mice
hous
anim
facil
saskatoon
cancer
center
anim
experi
carri
accord
canadian
council
anim
care
guidelin
construct
recombin
advexpress
ova
adv
ova
perform
insert
ova
gene
clone
pacova
vector
obtain
dr
bevan
univers
washington
seattl
washington
pshuttl
vector
stratagen
la
jolla
ca
form
plpaovaexpress
ova
gene
figur
pmeidigest
shuttl
vector
cotransform
escherichia
coli
cell
alreadi
contain
backbon
vector
increas
effici
homolog
recombin
form
recombin
adv
ova
recombin
adv
ova
vector
linear
paci
digest
transfect
cell
use
lipofectamin
gibcobrl
burlington
ontario
canada
gener
adv
ova
recombin
adv
combin
adenovir
vaccin
ab
therapi
chen
et
al
express
rat
neu
gene
control
adv
null
without
insert
transgen
figur
previous
construct
laboratori
recombin
adv
amplifi
cell
purifi
seri
cesium
chlorid
ultracentrifug
gradient
store
use
lymphocyt
drainag
lymph
node
mice
sc
immun
advova
pfu
per
mous
harvest
day
immun
stain
ab
ab
analyz
flow
cytometri
assess
kill
activ
perform
chromiun
assay
lymphocyt
deriv
immun
mous
drainag
lymph
node
use
target
effector
cell
respect
tetram
stain
mice
immun
iv
inject
adv
ova
pfu
per
mous
differ
day
immun
ml
mous
peripher
blood
stain
fitcconjug
ab
peconjug
b
ova
tetram
min
room
temperatur
analyz
flow
cytometri
fvbneun
tg
mice
immun
iv
inject
adv
pfu
per
mous
eleven
day
immun
ml
mous
peripher
blood
incub
fitcconjug
ab
pelabel
q
peptid
tetram
min
room
temperatur
analyz
flow
cytometri
vivo
cytotox
assay
mous
spleen
cell
puls
ovai
peptid
strongli
label
carboxylfluorescein
succinimidyl
ester
cfse
mm
cfse
high
serv
ovaspecif
target
cell
wherea
spleen
cell
puls
irrelev
peptid
weakli
label
cfse
mm
cfse
low
serv
nonspecif
control
target
cell
respect
eleven
day
follow
immun
adv
ova
immun
mice
iv
inject
cfse
high
cfse
low
mixtur
splenocyt
target
sixteen
hour
target
cell
deliveri
spleen
recipi
mice
remov
rel
proport
cfse
high
cfse
low
target
cell
remain
spleen
analyz
flow
cytometri
three
type
anim
studi
conduct
first
type
anim
studi
perform
evalu
prevent
antitumor
immun
wildtyp
mice
mice
per
group
sc
vaccin
adv
ova
pfu
per
mous
eleven
day
immun
mice
sc
inject
right
thigh
ova
tumor
cell
cell
per
mous
assess
cellular
mechan
adv
ovainduc
antitumor
immun
mice
ip
inject
ab
mg
per
mous
deplet
cell
nk
cell
day
adv
ova
immun
one
day
ab
treatment
mice
challeng
sc
inject
ova
cell
per
mous
ab
treatment
repeat
everi
day
total
five
time
assess
longterm
immun
mice
also
sc
inocul
ova
cell
per
mous
day
immun
second
type
anim
studi
perform
evalu
prevent
breast
carcinogenesi
tg
fvbneun
mice
mice
per
group
age
month
vaccin
sc
adv
pfu
per
mous
interv
total
five
vaccin
spontan
breast
tumor
develop
monitor
weekli
month
third
type
anim
studi
design
evalu
therapeut
antitumor
immun
fvbneun
mice
mice
per
group
sc
inject
cell
per
mous
cell
mous
monitor
weekli
tumor
growth
measur
two
perpendicular
diamet
use
calip
tumor
volum
mm
calcul
use
formula
v
b
largest
b
smallest
diamet
repres
tumor
grew
size
mm
earli
stage
around
day
tumor
cell
inject
mm
well
establish
around
day
tumor
cell
inject
tumorbear
fvbneun
tg
mice
sc
inject
adv
pfu
per
mous
interv
total
three
time
mimic
clinic
administr
trastuzumab
patient
load
dose
mg
trastuzumab
per
kg
patient
bodi
weight
tumorbear
mice
also
ip
inject
ab
dose
mg
kg
mous
bodi
weight
everi
day
total
five
time
anoth
tumorbear
mous
group
mice
treat
adv
ab
tumor
growth
monitor
daili
day
ethic
reason
mice
tumor
achiev
size
mm
volum
kill
statist
analys
conduct
use
prism
softwar
graphpad
softwar
san
diego
ca
perform
logrank
test
compar
mous
surviv
group
determin
signific
differ
group
student
ttest
perform
pvalu
consid
statist
signific
combin
adenovir
vaccin
ab
therapi
chen
et
al
adv
ova
stimul
ovaspecif
function
ctl
nk
respons
wildtyp
mice
assess
cellular
immun
respons
iv
immun
wildtyp
mice
recombin
ovaexpress
adenoviru
adv
ova
evalu
ovaspecif
tcell
respons
mous
peripher
blood
use
ab
b
ova
tetram
stain
flow
cytometri
found
adv
ova
vaccin
stimul
sustain
ovaspecif
tcell
respons
account
total
tcell
popul
figur
significantli
larger
mice
immun
control
adv
null
ovaspecif
tcell
respons
peak
day
immun
declin
slowli
assess
function
effect
cell
perform
vivo
cytotox
assay
adopt
transfer
ovai
peptidepuls
splenocyt
strongli
label
cfse
cfse
high
well
control
peptid
splenocyt
weakli
label
cfse
cfse
low
recipi
mice
vaccin
adv
ova
expect
substanti
loss
cfse
high
ovai
peptidepuls
cell
adv
ova
immun
mice
wherea
littl
cytotox
induc
mice
immun
control
adv
null
figur
indic
adv
ova
vaccin
effici
stimul
tcell
differenti
function
ovaspecif
ctl
effector
assess
potenti
advstimul
nk
respons
lymphocyt
mice
sc
immun
advova
harvest
drainag
lymph
node
day
immun
analyz
nk
activ
kill
activ
flow
cytometri
vitro
cytotox
assay
respect
shown
figur
proport
activ
nk
cell
significantli
greater
adv
advnul
advova
treat
mice
compar
control
mice
addit
nk
cell
deriv
adv
advnul
advova
treat
mice
display
stronger
kill
activ
tumor
cell
nk
cell
control
wildtyp
mice
figur
indic
advova
stimul
nonspecif
nk
cell
respons
adv
ova
stimul
ctlmediat
antitumor
immun
longterm
tcell
memori
wildtyp
mice
assess
prevent
antitumor
immun
aboveimmun
mice
sc
challeng
ovaexpress
melanoma
day
subsequ
immun
found
mice
immun
control
adv
null
die
tumor
within
day
subsequ
tumor
cell
challeng
wherea
mice
immun
adv
ova
tumor
free
figur
indic
adv
ova
stimul
prevent
antitumor
immun
mice
assess
cellular
mechan
antitumor
immun
treat
immun
mice
ab
deplet
nk
cell
respect
tumor
cell
challeng
demonstr
mice
treatment
ab
antink
ab
lost
antitumor
protect
indic
combin
adenovir
vaccin
ab
therapi
chen
et
al
adv
ova
induc
antitumor
immun
mainli
mediat
ctl
assess
longterm
immun
adv
ova
immun
mice
challeng
sc
inocul
ova
tumor
cell
day
immun
found
none
immun
mice
grew
tumor
figur
indic
adv
ova
vaccin
also
induc
longterm
antitumor
immun
adv
stimul
function
ctl
respons
lead
reduct
breast
carcinogenesi
tg
fvbneun
mice
tg
fvbneun
mice
neuspecif
selfimmun
toler
spontan
develop
multipl
neuexpress
breast
cancer
differ
size
differ
age
figur
b
tg
mice
extens
use
evalu
immunotherapeut
assess
tcell
respons
peripher
blood
sampl
mice
immun
advneu
harvest
day
immun
stain
ab
q
peptid
tetram
analyz
flow
cytometri
found
adv
stimul
tcell
respons
account
total
tcell
popul
figur
indic
adv
stimul
tcell
respons
tg
fvbneun
mice
immun
toler
determin
whether
adv
induc
cellular
immun
respons
could
reduc
breast
carcinogenesi
tg
fvbneun
mice
age
month
vaccin
sc
adv
interv
total
four
vaccin
shown
figur
adv
vaccin
protect
mice
breast
carcinogenesi
induc
signific
delay
tumor
format
mice
compar
control
adv
null
vaccin
indic
adv
vaccin
partli
overcom
immun
toler
reduc
breast
carcinogenesi
tg
fvbneun
mice
adv
adjuv
ab
therapi
wellestablish
tumor
tg
fvbneun
mice
assess
potenti
therapeut
effect
neuexpress
tg
mice
repeat
experi
use
adv
vaccin
combin
adenovir
vaccin
ab
therapi
chen
et
al
neuexpress
tumorbear
tg
fvbneun
mice
selfimmun
toler
found
vaccin
mice
bear
earli
stage
mm
breast
cancer
die
cancer
within
day
initi
vaccin
though
mous
surviv
prolong
figur
demonstr
ab
potent
therapeut
effect
establish
tumor
mice
assess
therapeut
effici
repeat
experi
use
ab
tumorbear
tg
fvbneun
mice
tumor
cell
grew
aggress
figur
found
vaccin
mice
bear
earli
stage
mm
breast
cancer
becam
tumor
free
figur
wherea
mice
bear
wellestablish
mm
tumor
surviv
though
mice
longer
surviv
figur
interestingli
found
mice
bear
wellestablish
tumor
free
tumor
mice
treat
adv
vaccin
combin
ab
therapi
wherea
remain
tumorbear
mice
longer
surviv
indic
vaccin
recombin
adenovir
vector
reduc
breast
carcinogenesi
also
provid
adjuv
effect
ab
therapi
erad
wellestablish
breast
cancer
tg
fvbneun
mice
immun
toler
convent
cancer
therapi
includ
surgeri
radiat
therapi
chemotherapi
demonstr
consider
clinic
success
past
year
howev
tumorfre
surviv
alway
accomplish
exampl
surgeri
radiat
therapi
quit
effect
treatment
local
tumor
often
palli
role
treatment
dissemin
diseas
chemotherapi
remain
treatment
modal
choic
sever
toxic
sideeffect
often
limit
use
identif
tumorassoci
ag
tumorspecif
tcell
respons
cancer
patient
led
develop
immunotherapi
aim
augment
antitumor
immun
respons
antitumor
immunotherapi
includ
activ
immunotherapi
use
variou
antitumor
vaccin
stimul
patient
antitumor
ctl
respons
adopt
immunotherapi
infus
antitumor
monoclon
ab
trastuzumab
tumorspecif
tumorinfiltr
lymphocyt
origin
murin
monoclon
antibodi
inhibit
tumor
growth
vivo
trastuzumab
human
monoclon
ab
direct
extracellular
domain
use
combin
chemotherapi
approv
fda
metastat
overexpress
breast
cancer
preclin
studi
demonstr
interest
properti
trastuzumab
includ
intern
degrad
protein
student
ttest
transgen
fvbneun
mice
age
month
vaccin
sc
adv
interv
total
four
vaccin
spontan
format
breast
tumor
monitor
weekli
vs
cohort
control
group
phosphatebuff
salin
pb
advnul
logrank
test
one
repres
experi
two
shown
adv
adenoviru
human
epiderm
growth
factor
receptor
combin
adenovir
vaccin
ab
therapi
chen
et
al
inhibit
cellcycl
progress
via
inhibit
mitogenactiv
protein
kinas
pathway
suppress
antiapoptot
phosphatidylinositol
akt
pathway
abdepend
cellular
cytotox
clinic
studi
shown
approxim
one
third
patient
advanc
neuposit
breast
cancer
respond
trastuzumab
monotherapi
trastuzumabbas
therapi
also
shown
effect
adjuv
neoadjuv
set
manag
earli
stage
breast
cancer
howev
one
major
limit
trastuzumab
immunotherapi
develop
ab
resist
usual
within
year
begin
treatment
metastat
set
schemat
resist
trastuzumab
may
deriv
truncat
activ
form
receptor
lack
trastuzumabbind
extracellular
domain
ii
constitut
activ
downstream
element
make
activ
pathway
independ
receptor
andor
iii
bypass
neureceptor
activ
anoth
transmembran
receptor
addit
risk
cardiac
toxic
especi
patient
previous
treat
anthracyclin
may
also
limit
use
trastuzumab
sinc
immun
respons
frequent
found
patient
breast
cancer
shown
preclin
model
immun
respons
associ
slower
tumor
develop
earli
stage
diseas
observ
togeth
report
efficaci
resist
passiv
trastuzumab
therapi
motiv
develop
variou
combinatori
immunotherapi
among
combin
therapeut
monoclon
antibodi
trastuzumab
variou
antitumor
vaccin
tumor
cell
dendrit
cell
dna
peptid
protein
viral
vector
promis
avenu
combin
immunotherapi
compar
passiv
immunotherapi
trastuzumab
vaccin
stimul
preexist
immun
respons
offer
sever
advantag
includ
fewer
iter
inject
ii
potenti
broader
use
patient
express
differ
level
iii
establish
memori
immun
respons
capabl
prevent
diseas
recurr
clinic
trial
demonstr
vaccin
could
incorpor
trastuzumab
therapi
result
repres
first
clinic
evid
potenti
benefit
minim
toxic
may
deriv
combin
immunotherapi
also
demonstr
combin
trastuzumab
follow
peptid
vaccin
safe
benefici
one
remark
featur
advbas
vaccin
abil
induc
except
high
sustain
frequenc
transgen
productspecif
tcell
respons
unlik
induc
subunit
vaccin
carrier
dna
vaccin
poxviru
vector
contract
initi
ctl
activ
studi
also
demonstr
adv
ova
vaccin
induc
sustain
ctl
respons
due
persist
ag
stimul
consist
previou
report
other
elucid
replicationdefect
adv
vector
genom
similar
wildtyp
adv
vector
acquir
natur
infect
persist
replicationdefect
adv
vector
found
muscl
site
inocul
liver
lymphat
tissu
experiment
anim
demonstr
adv
vaccin
stimul
tumor
grew
size
mm
earli
stage
tumorbear
fvbneun
tg
mice
sc
inject
adv
interv
total
three
time
ip
inject
mous
neu
antibodi
everi
day
total
five
time
c
tumor
grew
size
mm
wellestablish
tumorbear
fvbneun
tg
mice
treat
antibodi
alon
adv
antibodi
similar
manner
describ
tumor
growth
monitor
daili
day
vs
cohort
control
group
phosphatebuff
salin
pb
antibodi
alon
respect
logrank
test
one
repres
experi
two
shown
adv
adenoviru
human
epiderm
growth
factor
receptor
combin
adenovir
vaccin
ab
therapi
chen
et
al
ab
ctl
respons
prevent
antitumor
immun
wildtyp
mice
howev
abl
reduc
breast
carcinogenesi
tg
mice
selfimmun
toler
though
surviv
prolong
studi
demonstr
adv
induc
function
cell
also
nk
respons
lead
protect
antitumor
immun
howev
cell
nk
cell
major
role
immun
consist
recent
report
wan
colleagu
previous
demonstr
vaccin
dendrit
cell
engin
express
result
signific
delay
tumor
format
howev
despit
stronger
immun
respons
dna
vaccin
reduc
breast
carcinogenesi
present
studi
demonstr
adv
vaccin
significantli
reduc
breast
carcinogenesi
tg
fvbneun
mice
selfimmun
toler
consist
anoth
recent
report
berzofski
et
al
therapeut
efficaci
adv
cancer
remain
controversi
exampl
adv
vaccin
found
ineffect
even
administ
earli
one
two
day
seed
tumor
cell
wildtyp
mice
convers
also
demonstr
recombin
adv
vaccin
effici
erad
advanc
establish
murin
breast
cancer
wildtyp
mice
studi
show
adv
vaccin
littl
therapeut
effect
preexist
tumor
adv
slightli
delay
breast
tumor
growth
cure
tumor
tg
fvbneun
mice
even
though
earli
stage
mm
differ
adv
therapeut
effect
seen
studi
previou
report
may
deriv
use
differ
type
mice
studi
use
tg
fvbneun
mice
immun
toler
wherea
myun
et
al
use
wildtyp
mice
comparison
howev
ab
therapi
much
effect
sinc
cure
earli
stage
mm
tumor
tg
fvbneun
mice
fail
erad
wellestablish
tumor
mm
bocangel
et
al
demonstr
combinatori
synergi
induc
vaccin
express
tumor
suppressor
gene
melanoma
differentiationassoci
trastuzumab
delay
growth
neuexpress
human
breast
cancer
nude
mice
interestingli
first
time
demonstr
combinatori
immunotherapi
ab
adv
vaccin
capabl
erad
tg
fvbneun
mice
bear
wellestablish
breast
cancer
mm
significantli
prolong
surviv
remain
tumorbear
mice
indic
synergist
effect
adv
vaccin
capabl
stimul
ctl
nonspecif
nk
cell
respons
ab
therapi
wellestablish
tumor
tg
fvbneun
mice
immun
toler
taken
togeth
demonstr
adenovir
vector
vaccin
stimul
ctl
nk
cell
respons
provid
adjuv
effect
neu
ab
therapi
result
suggest
adjuv
effect
adv
ab
therapi
combinatori
immunotherapi
trastuzumab
adv
vaccin
may
use
new
therapeut
strategi
treatment
advanc
breast
cancer
author
declar
conflict
interest
